Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 3/2017

01-06-2017 | Letter to the Editor

Emetine induces estrogen receptor alpha degradation and prevents 17β-estradiol-induced breast cancer cell proliferation

Authors: Claudia Busonero, Stefano Leone, Filippo Acconcia

Published in: Cellular Oncology | Issue 3/2017

Login to get access

Excerpt

Dear Editor, …
Literature
1.
E. Ciruelos, T. Pascual, M.L. Arroyo Vozmediano, M. Blanco, L. Manso, L. Parrilla, C. Munoz, E. Vega, M.J. Calderon, B. Sancho, H. Cortes-Funes, The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. Breast 23, 201–208 (2014)CrossRefPubMed
2.
D.P. McDonnell, S.E. Wardell, J.D. Norris, Oral selective estrogen receptor Downregulators (SERDs), a breakthrough endocrine therapy for breast cancer. J. Med. Chem. 58, 4883–4887 (2015)CrossRefPubMedPubMedCentral
3.
P. Totta, C. Busonero, S. Leone, M. Marino, F. Acconcia, Dynamin II is required for 17beta-estradiol signaling and autophagy-based ERalpha degradation. Sci. Rep. 6, 23727 (2016)CrossRefPubMedPubMedCentral
4.
5.
P.K. Mehrotra, S. Kitchlu, A. Dwivedi, P.K. Agnihotri, S. Srivastava, R. Roy, A.P. Bhaduri, Emetine ditartrate: A possible lead for emergency contraception. Contraception 69, 379–387 (2004)CrossRefPubMed
6.
E. Cuyas, B. Martin-Castillo, B. Corominas-Faja, A. Massaguer, J. Bosch-Barrera, J.A. Menendez, Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties. Cell Cycle 14, 3527–3532 (2015)CrossRefPubMedPubMedCentral
7.
H.R. Chen, D.H. Sherr, Z. Hu, C. DeLisi, A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer. BMC Med. Genet. 9, 51 (2016)
8.
R. Wurth, S. Thellung, A. Bajetto, M. Mazzanti, T. Florio, F. Barbieri, Drug-repositioning opportunities for cancer therapy: Novel molecular targets for known compounds. Drug Discov. Today 21, 190–199 (2016)CrossRefPubMed
9.
J.V. Watson, S.H. Chambers, P.J. Smith, A pragmatic approach to the analysis of DNA histograms with a definable G1 peak. Cytometry 8, 1–8 (1987)CrossRefPubMed
Metadata
Title
Emetine induces estrogen receptor alpha degradation and prevents 17β-estradiol-induced breast cancer cell proliferation
Authors
Claudia Busonero
Stefano Leone
Filippo Acconcia
Publication date
01-06-2017
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 3/2017
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-017-0322-z

Other articles of this Issue 3/2017

Cellular Oncology 3/2017 Go to the issue

Original Paper

Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition

Review

Breast cancer metastasis: Putative therapeutic role of vascular cell adhesion molecule-1

Original Paper

Synthetic lethal targeting of RNF20 through PARP1 silencing and inhibition

Original Paper

Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss

Report

Epigenetic sampling effects: nephrectomy modifies the clear cell renal cell cancer methylome

Original Paper

Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits